Alseres Pharmaceuticals, Inc. (ALSE) Income Statement

Revenues	18.43K
Research and development
General and administrative	334.63K
Purchased in-process research and development
Total operating expenses	335.56K
Loss from operations	-317.12K
Gain on early extinguishment of debt
Other income (expense)
Interest expense, net	-3.88K
Investment income
Net loss	-321K
Preferred stock beneficial conversion feature
Accrual of preferred stock dividends and modification of warrants held by preferred stockholders
Net loss attributable to common stockholders
Basic and diluted net loss attributable to common stockholders per share
Weighted average common shares outstanding

Entities mentioned with ALSE

View All Entities